Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy

M Brendel; H Barthel; T Van Eimeren; K Marek; L Beyer; M Song; C Palleis; M Gehmeyr; U Fietzek; G Respondek; J Sauerbeck; A Nitschmann; C Zach; J Hammes; MT Barbe; O Onur; F Jessen; D Saur; ML Schroeter; JJ Rumpf; M Rullmann; A Schildan; M Patt; B Neumaier; O Barret; J Madonia; DS Russell; A Stephens; S Roeber; J Herms; K Bötzel; J Classen; P Bartenstein; V Villemagne; J Levin; GU Höglinger; A Drzezga; J Seibyl; O Sabri

Journal article

Assessment of 18F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy

M Brendel, H Barthel, T Van Eimeren, K Marek, L Beyer, M Song, C Palleis, M Gehmeyr, U Fietzek, G Respondek, J Sauerbeck, A Nitschmann, C Zach, J Hammes, MT Barbe, O Onur, F Jessen, D Saur, ML Schroeter, JJ Rumpf Show all

JAMA Neurology | AMER MEDICAL ASSOC | Published : 2020

DOI: 10.1001/jamaneurol.2020.2526

Download PDF

Abstract

Importance: Progressive supranuclear palsy (PSP) is a 4-repeat tauopathy. Region-specific tau aggregates establish the neuropathologic diagnosis of definite PSP post mortem. Future interventional trials against tau in PSP would strongly benefit from biomarkers that support diagnosis. Objective: To investigate the potential of the novel tau radiotracer 18F-PI-2620 as a biomarker in patients with clinically diagnosed PSP. Design, Setting, and Participants: In this cross-sectional study, participants underwent dynamic 18F-PI-2620 positron emission tomography (PET) from 0 to 60 minutes after injection at 5 different centers (3 in Germany, 1 in the US, and 1 in Australia). Patients with PSP (incl..

View full abstract